Brexanolone History and Updates

37 events · 2018 – present

Synced daily from openFDA and ClinicalTrials.gov. Last sync: .

0
FDA Approvals
0
Label Revisions
37
Trial Milestones
0
Pivotal Publications
Brexanolone — history and updatesFDA approvals, label revisions, recalls, trials, and pivotal publicationsFDA approvalsLabel revisionsRecalls + safetyTrialsPublications201920202021202220232024202520262027Trial: NCT06580444 2025-07-28 → 2027-02-26 (primary completion)Trial: NCT05223829 2023-08-01 → 2025-12-31 (primary completion)Trial: NCT05254405 2023-06-01 → 2025-12-30 (primary completion)Trial: NCT05645432 2023-05-10 → 2023-11-21 (primary completion)Trial: NCT05329779 2022-11-04 → 2023-07-18 (primary completion)Trial: NCT05543746 2022-08-05 → 2023-11-15 (primary completion)Trial: NCT05314153 2022-02-23 → 2024-06-01 (primary completion)Trial: NCT04537806 2020-12-18 → 2021-07-01 (primary completion)Trial: NCT04273191 2020-02-29 → 2021-08-31 (primary completion)Trial: NCT03665038 2018-09-07 → 2021-01-08 (primary completion)Results posted — 2022-07-27 Trial results posted: NCT04537806 A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)Results posted — 2022-08-11 Trial results posted: NCT03665038 A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)Results posted — 2024-12-12 Trial results posted: NCT05645432 An Open-Label Study Evaluating Brexanolone in Adults With TinnitusResults posted — 2025-01-28 Trial results posted: NCT05543746 Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum DepressionResults posted — 2026-01-22 Trial results posted: NCT05329779 Study on Allopregnanolone and Depression in Perimenopausal Womentoday (2026-05-25)FDA approvalLabel revisionRecall or safetyTrial activityPivotal publication

Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-05-25Download chart as PNG

This page tracks every FDA action, clinical trial milestone, and major publication for Brexanolone since 2018, drawn from openFDA, ClinicalTrials.gov, and PubMed.

All published updates (1)

Upcoming & expected milestones

Past events

2026
2025
Primary completion· ClinicalTrials.gov
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
Trial started· ClinicalTrials.gov
Brexanolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Results posted· ClinicalTrials.gov
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
2024
2023
Primary completion· ClinicalTrials.gov
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Trial started· ClinicalTrials.gov
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
Trial started· ClinicalTrials.gov
An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress Disorder
2022
Results posted· ClinicalTrials.gov
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Trial started· ClinicalTrials.gov
Dynamic Neural Mechanisms of Brexanolone-induced Antidepressant Effects in Postpartum Depression
Results posted· ClinicalTrials.gov
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
2021
Primary completion· ClinicalTrials.gov
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
Primary completion· ClinicalTrials.gov
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Primary completion· ClinicalTrials.gov
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
2020
Trial started· ClinicalTrials.gov
A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19)
Trial started· ClinicalTrials.gov
A Study to Evaluate Multimodal Neuroimaging Parameters in Women With Postpartum Depression Who Are Receiving ZULRESSO™ (Brexanolone)
2019
2018
Trial started· ClinicalTrials.gov
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

Sources

FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.